GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Total Inventories

Cutia Therapeutics (HKSE:02487) Total Inventories : HK$69.7 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Total Inventories?

Cutia Therapeutics's total inventories for the quarter that ended in Jun. 2024 was HK$69.7 Mil. Cutia Therapeutics's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Jun. 2024 was HK$59.6 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Cutia Therapeutics's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was HK$2.80.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Cutia Therapeutics's Days Inventory for the six months ended in Jun. 2024 was 223.41.

Inventory Turnover measures how fast the company turns over its inventory within a year. Cutia Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2024 was 0.82.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Cutia Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.58.

Cutia Therapeutics Total Inventories Historical Data

The historical data trend for Cutia Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics Total Inventories Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Total Inventories
2.21 22.33 49.56 79.75

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Inventories Get a 7-Day Free Trial 22.33 22.91 49.56 69.68 79.75

Cutia Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Cutia Therapeutics  (HKSE:02487) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Cutia Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is

Net-Net Working Capital Per Share (Q: Jun. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1118.629+0.75 * 57.389+0.5 * 69.676-343.895
-0-0)/304.739
=2.80

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cutia Therapeutics's Days Inventory for the six months ended in Jun. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2024 )/Cost of Goods Sold (Q: Jun. 2024 )*Days in Period
=59.6195/48.703*365 / 2
=223.41

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Cutia Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2024 ) / Average Total Inventories (Q: Jun. 2024 )
=48.703 / 59.6195
=0.82

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cutia Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=59.6195 / 102.891
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Cutia Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Cutia Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Total Inventories
Comparable Companies
HKSE:02509 HKSE:02137 HKSE:02566 HKSE:02563 HKSE:06978 HKSE:06996 HKSE:01541 HKSE:03681 HKSE:02181 HKSE:01875 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Website
https://www.cutiatx.com
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.
Executives
Zhang Lele 2101 Beneficial owner
Zhang Qiping 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p. 2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Yf Dermatology Limited 2101 Beneficial owner
Yunfeng Capital Limited 2102 Investment manager
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you

Cutia Therapeutics Headlines

No Headlines